GLP-1 drugs, the treatment class popularized by Eli Lilly (LLY) and Novo Nordisk (NVO), could generate $150B in global sales ...
Zacks Investment Research on MSN
Can Eli Lilly's 2026 acquisition spree diversify growth beyond GLP-1s?
Eli Lilly LLY has pursued a series of acquisitions since early 2026 to strengthen its pipeline and support long-term growth ...
TD Cowen has lifted its global GLP-1 sales forecast to $150 billion by 2030, up from its prior $139 billion estimate issued just over a y ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results